TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: overall rate of intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of unfavorable discharge to a skilled-nursing facility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 36‐Item Short Form Health Survey‐physical health summary measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: worry symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative scores of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlations between historical PA recall and PA questionnaires
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PS volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving enteral autonomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute PST reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cFGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: xerostomia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage body weight change after training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual pressure gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuronal apoptosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AchE activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tenderness/pain
Endpoint domain: Adverse events/effects
Primary endpoint: Favorable outcome improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poststimulation mean peak plasma cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 8-hour plasma cortisol area under the curve values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of goiter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of attention‐deficit hyperactivity disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of IQ less than 85
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in SCT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death due to any cause, non-fatal myocardial infarction, non-fatal stroke, unstable angina, congestive heart failure requiring hospital admission, or any type of coronary revascularization
Endpoint domain: Mortality/survival
Primary endpoint: U1-Stm distance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing depth (PD) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increased resting DMN activity in the precuneus region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in SB episodes per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of MMP‐9 and TIMP‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MMP‐9/TIMP‐1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Gastric pHi value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma concentrations of DAO and endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall satisfaction with the telerehabilitation assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergency Department revisits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Calmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to unbound paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle power improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥50% responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testicular atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response (CR) in preventing CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Significant Nausea (NSN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving clear or almost clear palms and soles (ppIGA 0/1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Palmoplantar Psoriasis Area and Severity Index (ppPASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index (DLQI) 0/1 responses
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite endpoint of coronary heart disease death plus non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Composite of fatal and non-fatal strokes
Endpoint domain: Mortality/survival
Primary endpoint: Immunosuppressive actions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: chest tube output in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body fluid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage of correct chest compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attendance at CR orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood flow response to adrenaline infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants viewing television for 3 or more hours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mortality or impairment/disability
Endpoint domain: Mortality/survival
Primary endpoint: Severe impairment or disability
Endpoint domain: Mortality/survival
Primary endpoint: Change in myocardial efficiency (WMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Technical skill (simulated pain scores, correct use of abdominal pressure, loop management)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mammography use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Motor Unified Parkinson's Disease Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction rate of bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial pancreatic polypeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Symptom Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: clinic systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: asleep diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fluoride concentrations in plaque fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboembolic events (TE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hazards of CVD
Endpoint domain: Mortality/survival
Primary endpoint: mean total cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low density lipoprotein cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cortisol reactivity (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean total production time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean chair time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean laboratory work time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hippocampal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: maximum plasma concentration (C(max)) of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration time curve (AUC(infinity)) of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of extrinsic stains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worse health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of unilateral spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hypotensive events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative pain/discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Elevation of the maxillary sinus floor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: anti-influenza neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Free erythrocyte protoporphyrin (FEP) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global Assessment of Functioning (GAF) ratings
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of ventricular premature beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatine kinase (CK) infarct weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angle of error
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Satisfaction with goal setting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived relevance of goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Autonomy in goal setting
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: progressive gain of dorsiflexion ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Treatment Satisfaction Questionnaire score change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumen reduction at the distal edge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque increase at the distal edge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptoms intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum exposure of tramadol and O‐desmethyltramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of exposure (AUC(0‐48)‐values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HADS-anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-12 Physical Component Summary (PCS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CSMS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of parenting intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention of parents in the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recruitment challenges for parents
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FMS (Functional Movement Screen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysholm Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee 2000 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health outcomes for gout patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for renal replacement therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incremental cost-effectiveness ratio per clinical event avoided
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost per life-year gained considering cardiovascular deaths
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost per life-year gained considering all-cause death
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uterine artery resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ovarian arterial impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Success in addressing spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidences of procedure-related hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of endocarditis-related bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ankle dorsiflexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: perception of gastric distension during euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastric compliance during hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PGFA (Percentage of Gutta-Percha Filled Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSFA (Percentage of Space Filled Area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durable objective responses (ORs)
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting insulin and glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: train-of-four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: HF-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: H. pylori stool antigen sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twenty-four-hour energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of clonal transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBV vaccination rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in allergy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Disappearance of clinical and functional signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TS (Tenderness Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of maternal allergic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total adenoma burden per subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lower problem or interference level related to numbness or decreased lip sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in positive and general psychopathology symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expense of isoflurane
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lateral pelvic displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased threshold for egg powder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustainability of exercise behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximal LV dP/dt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dentin hardening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentin darkening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the size of the lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IOP reduction after ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Heavy drinking prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequent drinking prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of memory CD4+ cells expressing CXCR5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CXCL13 mRNA levels in thyroid tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CXCR5 mRNA levels in thyroid tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: UL movement acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: JTHF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Osseointegration (% OI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of lamellar bone to woven bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular arrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of APR (Adverse Psychological Reaction)
Endpoint domain: Adverse events/effects
Primary endpoint: skin temperature of the digits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: lice-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic UTI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to CRCS guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of theophylline clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-soluble vitamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma norepinephrine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma neuropeptide Y concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OQoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of days to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days to lapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage days of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total exposure to IDeg during one dosing interval at steady state (AUCIDeg,τ,SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total glucose-lowering effect of IDeg (AUCGIR,τ,SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes